Clinical trials · Minnesota
Esophageal Adenocarcinoma clinical trials in Minnesota
We’re tracking 18 recruiting esophageal adenocarcinoma studies with a site in Minnesota — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Minnesota
- NCT06078709RecruitingPhase 2
Pre-surgery radiation and chemo for esophageal cancer
This trial tests a shorter course of radiation combined with chemotherapy (FOLFOX) before surgery for esophageal or stomach-junction cancer. It aims to reduce side effects and still improve outcomes.
Rochester, MinnesotaAges 18 years+ - NCT03801876RecruitingPhase 3
Proton versus photon radiation for esophageal cancer
This trial compares proton therapy and standard photon (X-ray) radiation for treating esophageal cancer. It looks to see which approach works better and is safer for people who need chemoradiation.
Northfield, MinnesotaAges 18 years+ - NCT06203600RecruitingPhase 2/Phase 3
Nivolumab plus standard treatment for advanced stomach or esophageal cancer
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Bemidji, MinnesotaAges 18 years+ - NCT05677490RecruitingPhase 3
Chemo options, with or without nivolumab, for HER2-negative stomach cancer
This Phase 3 trial compares two standard chemotherapy regimens for advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-negative. It also tests whether adding nivolumab (an immune therapy) improves outcomes.
Aitkin, MinnesotaAges 18 years+ - NCT03961945Recruiting
Testing a new way to diagnose Barrett’s esophagus
This study tests minimally invasive, sample-based tests during an endoscopy to find Barrett’s esophagus and help sort it from esophageal cancer risk. It may help doctors spot changes earlier and more accurately using less invasive methods than standard tissue testing alone.
Austin, MinnesotaAges 18–90 - NCT07212491Enrolling by invitation
New ways to detect early esophageal changes in Barrett's esophagus
This study tests a new, less invasive way to detect precancerous changes or early cancer in Barrett's esophagus. It uses a sponge or brush to collect cells from your esophagus during a routine endoscopy, which may help find problems earlier and avoid more invasive procedures.
Rochester, MinnesotaAges 18–90 - NCT06005493RecruitingPhase 1/Phase 2
Study of AZD5863 for advanced stomach, esophagus, or pancreatic cancer
This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.
Rochester, MinnesotaAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Burnsville, MinnesotaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Saint Paul, MinnesotaAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Minneapolis, MinnesotaAges 18 years+ - NCT07221149RecruitingPhase 2/Phase 3
Pumitamig vs Nivolumab for untreated stomach or esophagus cancer
This trial compares two treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combination works better.
Rochester, MinnesotaAges 18 years+ - NCT00288119Recruiting
Study genes in Barrett’s esophagus and esophageal cancer
This study looks at genetic (inherited) factors that may be linked to Barrett’s esophagus and esophageal cancer. It may help researchers understand why these conditions happen in some families and others do not.
Rochester, MinnesotaAges 18 years+ - NCT06071845Recruiting
Testing a simpler sponge test for Barrett's esophagus
This study tests a new, less invasive way to collect cells from the esophagus using a small sponge on a string (called Cytosponge). It aims to see if this method can accurately detect Barrett's esophagus, a condition that can raise the risk of esophageal cancer.
Rochester, MinnesotaAges 18–90 - NCT05530343Recruiting
Two ways to sample tissue during Barrett’s follow-up
This study compares two tissue-collection methods during an endoscopy for Barrett’s esophagus to see which one detects concerning changes better. Your results could help improve how doctors check Barrett’s over time.
Rochester, MinnesotaAges 18–89 - NCT00587314Enrolling by invitation
Testing ablation treatment for Barrett’s with precancer changes
This trial studies whether an “ablation” procedure (destroying abnormal esophagus lining) works well for people with Barrett’s esophagus that has high-grade precancer changes or very early cancer. It may help find safer or more effective ways to prevent the condition from worsening.
Rochester, MinnesotaAges 18–90 - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
Rochester, MinnesotaAges 18–90 - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Rochester, MinnesotaAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Aitkin, MinnesotaAges 40–75
Where these studies are running in Minnesota
Institutions with a site for the recruiting esophageal adenocarcinoma studies listed above.
- Mayo Clinic · 10 studies
- Mercy Hospital · 5 studies
- United Hospital · 4 studies
- Abbott-Northwestern Hospital · 3 studies
- Essentia Health - Deer River Clinic · 3 studies
- Essentia Health Cancer Center · 3 studies
- Essentia Health Hibbing Clinic · 3 studies
- Essentia Health Saint Joseph's Medical Center · 3 studies
What taking part in a esophageal adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Esophageal Adenocarcinoma trials in other states
Common questions
- Are there esophageal adenocarcinoma clinical trials in Minnesota?
- Yes. We're currently tracking 18 recruiting esophageal adenocarcinoma studies with a site in Minnesota, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a esophageal adenocarcinoma study in Minnesota?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Minnesota to take part?
- Not necessarily. These studies have a site in Minnesota, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a esophageal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New esophageal adenocarcinoma studies open in Minnesota regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.